Spots Global Cancer Trial Database for braf v600 mutation
Every month we try and update this database with for braf v600 mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | NCT05275374 | Cancer BRAF V600 Mutat... Melanoma Colorectal Canc... Thyroid Cancer Nonsmall Cell L... | XP-102 Trametinib | 18 Years - | Xynomic Pharmaceuticals, Inc. | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. | NCT03514901 | Melanoma Metast... BRAF V600 Mutat... | Experimental co... Pembrolizumab o... | 18 Years - | Intergruppo Melanoma Italiano | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | NCT03332589 | Malignant Melan... Brain Metastase... | E6201 E6201 plus dabr... | 18 Years - | Spirita Oncology, LLC | |
| A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) | NCT05546905 | Metastatic Non-... BRAF V600 Mutat... | 18 Years - | Pierre Fabre Medicament | ||
| A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | NCT01543698 | Solid Tumors Ha... | LGX818 MEK162 LEE011 | 18 Years - | Pfizer | |
| Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | NCT04759846 | BRAF V600 Mutat... Unresectable Me... Metastatic Mela... Hepatic Impairm... | Encorafenib + B... Encorafenib + B... Encorafenib + B... | 18 Years - | Pierre Fabre Medicament | |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. | NCT03514901 | Melanoma Metast... BRAF V600 Mutat... | Experimental co... Pembrolizumab o... | 18 Years - | Intergruppo Melanoma Italiano | |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | NCT02836548 | Melanoma Skin Neoplasms | Vorinostat | - | The Netherlands Cancer Institute | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | NCT05800340 | Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski... | Toripalimab Nab paclitaxel Pemetrexed Carboplatin | 18 Years - | Guangdong Provincial People's Hospital | |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations | NCT06054191 | NSCLC BRAF V600 Mutat... MET Exon 14 Mut... | Dabrafenib + Tr... Capmatinib | 18 Years - | Sun Yat-sen University | |
| Advanced Melanoma in Russian Experience | NCT03663647 | Cutaneous Melan... BRAF V600 Mutat... | 18 Years - 89 Years | MelanomaPRO, Russia | ||
| A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors | NCT05501912 | Advanced Solid ... BRAF V600 Mutat... | ABM-1310 | 18 Years - 80 Years | ABM Therapeutics Shanghai Company Limited | |
| Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | NCT05103891 | Melanoma BRAF V600 Mutat... Unresectable Me... Metastatic Mela... | Binimetinib Ora... | 18 Years - 65 Years | Pierre Fabre Medicament | |
| Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | NCT05810740 | Melanoma BRAF V600 Mutat... Unresectable Me... Metastatic Mela... | Binimetinib Ora... | 18 Years - 65 Years | Pierre Fabre Medicament | |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | NCT03332589 | Malignant Melan... Brain Metastase... | E6201 E6201 plus dabr... | 18 Years - | Spirita Oncology, LLC | |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. | NCT03514901 | Melanoma Metast... BRAF V600 Mutat... | Experimental co... Pembrolizumab o... | 18 Years - | Intergruppo Melanoma Italiano | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) | NCT05546905 | Metastatic Non-... BRAF V600 Mutat... | 18 Years - | Pierre Fabre Medicament | ||
| Dabrafenib and/or Trametinib Rollover Study | NCT03340506 | Melanoma Non Small Cell ... Solid Tumor Rare Cancers High Grade Glio... | dabrafenib trametinib | 18 Years - 100 Years | Novartis | |
| Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | NCT05810740 | Melanoma BRAF V600 Mutat... Unresectable Me... Metastatic Mela... | Binimetinib Ora... | 18 Years - 65 Years | Pierre Fabre Medicament | |
| Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors | NCT04190628 | Advanced Solid ... BRAF V600 Mutat... | ABM-1310 Cobimetinib | 18 Years - | ABM Therapeutics Corporation | |
| A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | NCT01436656 | Melanoma and Me... | LGX818 | 18 Years - | Pfizer | |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | NCT04741997 | Melanoma Stage ... Melanoma Stage ... BRAF V600 Mutat... | Encorafenib Pil... Binimetinib Pil... Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
